Allison Gatlin
Investors.com
Charlotte, NC, United States
Contact Allie
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Allie:
Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS Treatment
Analysts saw just $4.7 million in sales of Relyvrio. Amylyx blew that out of the water. → Read More
Biotech Stocks And The SVB Collapse — Here's What We Know
The collapse of SVB will have a big impact on early-stage, venture-backed companies. → Read More
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
These companies aren't working on a vaccine, but a monoclonal antibody. → Read More
Why Penumbra CEO Adam Elsesser Says It's Going To Be 'The Most Extraordinary Year'
Penumbra is reimagining how to remove blood clots safely and routinely. → Read More
Could Merck's Next Keytruda-Like Franchise Generate $10 Billion In Sales?
The heart segment is becoming more important as Keytruda near patent expiration. → Read More
Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit
The FDA is set to review the company's neurological drug by Tuesday. → Read More
'Here We Go Again': Seagen Soars As Pfizer Reportedly Mulls A Takeover
The potential deal follows rumors last year that Merck could buy Seagen. → Read More
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. → Read More
Dexcom Slumps As A New Rival Reportedly Arrives On Scene: Apple
Apple is reportedly making a bid for the diabetes market with new Apple Watch tech. → Read More
Shockwave Medical Just Tripled Profit Expectations, Delivering 991% Growth
The company also beat sales expectations, meeting the high end of its outlook. → Read More
A Patent Cliff Is Coming For Bristol Myers — Can Billions In New Products Fill The Gap?
The company's biggest moneymakers are soon to lose patent protection. → Read More
IBD Stock Of The Day Dexcom Bounds Off A New Entry After Topping Bullish Calls
The stock ranks in the top 9% of all stocks when it comes to profitability. → Read More
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Danaher is reportedly looking to add to its wheelhouse to compete with Thermo. → Read More
Eli Lilly Dives After A 'Bump In The Road' Shakes Its Newest Diabetes Drug
One analyst called the sales miss an overreaction considering Lilly's efforts in obesity, sleep apnea and diabetes-related diseases. → Read More
Prime-Time Battles Drive GSK And Novo Nordisk In 2023; Novartis Preps Its Spinoff
As GSK and Novo prep for battles in RSV and obesity, Novartis is planning a spinoff. → Read More
Abbott Laboratories Skids As Covid Tests Weigh On Organic Growth
Overall sales topped forecasts, but organic growth missed expectations. → Read More
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
Some patients improved while taking the company's twice-daily pill. → Read More
How J&J's Mostly Defunct Covid Shot Still Managed To Hamper Sales; Danaher Dives
Both J&J and Danaher were hampered Tuesday by Covid vaccines. → Read More
An Unexpected Feat Just Sent Pliant Therapeutics Soaring 35%
The company has a potentially best-in-class approach to a lung condition. → Read More
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Shares have sat atop the IBD 50 for weeks, have perfect ratings and recently hit a profit-taking zone. → Read More